Homepage4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Vorige slotkoers
¥ 2.325,00
Dag-range
¥ 2.302,00 - ¥ 2.345,00
Jaar-range
¥ 1.921,00 - ¥ 2.505,00
Beurswaarde
122,71 mld. JPY
Gem. volume
74,36K
Koers/winst
13,51
Dividendrendement
1,95%
Primaire beurs
TYO
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(JPY) | dec 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 22,35 mld. | 5,23% |
Bedrijfskosten | 12,67 mld. | 8,68% |
Netto inkomsten | 2,16 mld. | -28,48% |
Netto winstmarge | 9,69 | -32,00% |
Winst per aandeel | — | — |
EBITDA | 5,68 mld. | -0,43% |
Effectief belastingtarief | 23,25% | — |
Balans
Totale activa
Totale passiva
(JPY) | dec 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 24,52 mld. | 25,51% |
Totale activa | 156,58 mld. | 2,30% |
Totale passiva | 71,34 mld. | -4,02% |
Totaal aandelenvermogen | 85,24 mld. | — |
Uitstaande aandelen | 44,08 mln. | — |
Koers-boekwaardeverhouding | 1,20 | — |
Rendement op activa | 6,01% | — |
Rendement op kapitaal | 7,27% | — |
Kasstroom
Nettomutatie in liquide middelen
(JPY) | dec 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 2,16 mld. | -28,48% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
CEO
Opgericht
22 dec 1955
Website
Werknemers
1.777